根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司Atossa Therapeutics已与Intas Pharmaceuticals及Jina Pharmaceuticals达成协议，三方承诺不对特定与Endoxifen相关的专利提出挑战。
该协议涉及Atossa Therapeutics核心产品Endoxifen的专利保护范围。Endoxifen是一种选择性雌激素受体调节剂，目前正针对乳腺癌治疗等领域开展临床研究。
此次不起诉协议的签署，意味着相关企业避免了潜在的专利法律纠纷，为Atossa Therapeutics推进Endoxifen的研发和商业化进程扫清了障碍。专利稳定性对生物技术公司的估值和合作伙伴关系具有重要影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.